Analysts think ANAB stock price could increase by 161%
Nov 21, 2024, 12:26 PM
-28.36%
What does ANAB do
AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
13 analysts think ANAB stock price will increase by 161.15%. The current median analyst target is $53.04 compared to a current stock price of $20.31. The lowest analysts target is $30.30 and the highest analyst target is $94.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
